Encompass Health

John Patrick Darby sold 8,906 shares of Encompass Health on August 10 for about $1.1 million, reducing his direct stake to 75,041 shares. The sale came after a strong quarter, raised guidance and a finalized Medicare rule boosting inpatient rehabilitation payments by roughly 2.3% from October, which should benefit the company's largely Medicare-covered patient mix. Management highlighted the reimbursement tailwind as a key driver of the outlook, though Encompass remains exposed to government-rate changes. Investors should monitor Medicare reimbursement updates rather than isolated insider trims. » More on finance.yahoo.com

Encompass Health CFO Douglas E. Coltharp sold 18,869 shares on August 10 for about $2.4 million but retains 241,000 shares valued at roughly $30.4 million, representing about 0.2% of outstanding stock. The sale was modest compared with a much larger CEO reduction the same day and came after results that drove the stock near a 52-week high: revenue rose ~10% to $1.6 billion, guidance was raised, and the company increased its dividend and authorized a $1 billion buyback. Encompass Health has a market capitalization near $12.5 billion, TTM revenue of $6.2 billion and net income of $621 million, and the CFO's trim does not appear to reflect operational concerns. » More on finance.yahoo.com

Encompass Health privately placed additional 5.875% senior notes (due 2034) with a principal amount of $100 million at 98.75%, generating net proceeds of about $96.9 million after fees. The company will use the proceeds and cash to partially repay its revolving credit facility. The new notes are pari passu with existing 5.875% senior notes due 2034 and were sold to qualified institutional buyers. Encompass Health also reported strong Q2 results with adjusted EPS of $1.55, above expectations, and raised its outlook. » More on de.investing.com